[Antibodies to infliximab and antigens HLA I-II class as the witnesses of immune response to the biological treatment of inflammatory bowel disease].
Despite combination therapy with immunosuppressive agents, 32.5% of patients with IBD showed the formation of antibodies to infliximab. Simultaneous study of the concentration of the drug (infliximab), TNF-alpha and antibodies to it in the blood serum allows to judge not only on the effectiveness of anticytokine therapy, but also on the advisability of further conducting therapy. Elevated levels of AINF may lead to infusion reactions, reducing the effectiveness and duration of response to this therapy. Transplantation of MSCs reduces the level of antibodies to infliximab, but in 2 (5%) patients noticed a gradual increase of these antibodies. After infliximab infusion from 4 to 8 weeks the level in serum increased up to 45 mg/ml and higher, further serological concentration of infliximab is gradually reduced and then falls below the-horn. High concentrations of infliximab (> 45 mkg/ml) in blood samples at combined immunosuppressive therapy (infliximab + glucocorticoids + cytotoxic agents) should be considered as a sign of potential complications. The absence of antibodies to antigens of HLA I and class II after systemic transplantation of allogeneic mesenchymal stromal cells (MSCs) of bone marrow demonstrates not only the effectiveness but also the safety of transplantation of allogeneic MSCs, in relation with that the special selection of donors for transplantation of allogeneic MSCs is not required.
V É
VÉ
Sagynbaeva
L B
LB
Lazebnik
O V
OV
Kniazev
L I
LI
Efremov
D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000097:blood / Q000276:immunology / Q000628:therapy; D000069285:Infliximab; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D008875:Middle Aged; D014184:Transplantation, Homologous
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D000069285:Infliximab